STOCKWATCH
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultMay 12, 2026, 04:13 PM

XOMA Royalty Q1 Net Income $4.47M, EPS $0.18; Operating Cash Flow Up

AI Summary

XOMA Royalty Corporation reported a net income of $4.47 million for the first quarter of 2026, a significant increase from $2.37 million in Q1 2025, with basic EPS rising to $0.18 from $0.06. This improvement was primarily driven by $3.55 million in gains on acquisitions and $4.76 million in other income, net, offsetting a decrease in total income and revenues to $12.32 million. The company also saw a substantial increase in net cash provided by operating activities, reaching $6.12 million. Total assets slightly decreased to $271.86 million, while total liabilities decreased to $158.96 million.

Key Highlights

  • Net income increased to $4.47 million in Q1 2026 from $2.37 million in Q1 2025.
  • Basic earnings per share rose to $0.18 in Q1 2026 from $0.06 in Q1 2025.
  • Total income and revenues decreased to $12.32 million in Q1 2026 from $15.91 million in Q1 2025.
  • Operating expenses increased to $12.80 million in Q1 2026 from $9.98 million in Q1 2025.
  • The company recorded $3.55 million in gains on acquisitions for Q1 2026.
  • Other income (expense), net, was $4.76 million in Q1 2026, compared to $(0.10) million in Q1 2025.
  • Net cash provided by operating activities increased to $6.12 million in Q1 2026 from $2.20 million in Q1 2025.
  • Cash and cash equivalents stood at $85.60 million as of March 31, 2026.
XOMA
Biotechnology: Pharmaceutical Preparations
XOMA Royalty Corp

Price Impact